Progressive improvement of T -scores in men with osteoporosis and subnormal serum testosterone levels upon treatment with testosterone over six years

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Haider, Ahmad ^a   Meergans, Ulrich ^b   Traish, Abdulmaged ^c   Saad, Farid ^d,e   Doros, Gheorghe ^f   Lips, Paul ^g   Gooren, Louis ^g,h  

^a Private Urology Practice   (Germany)

^b Department of Orthopedics   (Germany)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYER PHARMA AG   (Germany)

^e GULF MEDICAL UNIVERSITY   (United Arab Emirates)

^f BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; TESTOSTERONE UNDECANOATE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABUSE; ANDROGEN DEFICIENCY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE DENSITY; CONTROLLED STUDY; CROHN DISEASE; CRYPTORCHISM; DRUG BLOOD LEVEL; HODGKIN DISEASE; HUMAN; HYPOGONADISM; KIDNEY TRANSPLANTATION; KLINEFELTER SYNDROME; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TESTIS DISEASE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84897766291     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/496948     Document Type: Article

References (46)

1. Laurent M., Gielen E., Claessens F., Boonen S., Vanderschueren D., Osteoporosis in older men: recent advances in pathophysiology and treatment. Best Practice & Research Clinical Endocrinology & Metabolism 2013 27 4 527 539 10.1016/j.beem.2013.04.010
2. Kannegaard P. N., van der Mark S., Eiken P., Abrahamsen B., Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age and Ageing 2010 39 2 203 209 2-s2.0-77949354742 10.1093/ageing/afp221
3. Travison T. G., Nguyen A.-H., Naganathan V., Stanaway F. F., Blyth F. M., Cumming R. G., Le Couteur D. G., Sambrook P. N., Handelsman D. J., Changes in reproductive hormone concentrations predict the prevalence and progression of the frailty syndrome in older men: the concord health and ageing in men project. The Journal of Clinical Endocrinology & Metabolism 2011 96 8 2464 2474 2-s2.0-79961221353 10.1210/jc.2011-0143
4. Callewaert F., Sinnesael M., Gielen E., Boonen S., Vanderschueren D., Skeletal sexual dimorphism: relative contribution of sex steroids, GH-IGF1, and mechanical loading. Journal of Endocrinology 2010 207 2 127 134 2-s2.0-78049380720 10.1677/JOE-10-0209
5. Fink H. A., Ewing S. K., Ensrud K. E., Barrett-Connor E., Taylor B. C., Cauley J. A., Orwoll E. S., Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. The Journal of Clinical Endocrinology & Metabolism 2006 91 10 3908 3915 2-s2.0-33749541914 10.1210/jc.2006-0173 (Pubitemid 44536863)
6. Tuck S. P., Francis R. M., Testosterone, bone and osteoporosis. Frontiers of Hormone Research 2009 37 123 132 2-s2.0-59849114732 10.1159/000176049
7. Bhasin S., Pencina M., Jasuja G. K., Travison T. G., Coviello A., Orwoll E., Wang P. Y., Nielson C., Wu F., Tajar A., Labrie F., Vesper H., Zhang A., Ulloor J., Singh R., D'Agostino R., Vasan R. S., Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the framingham heart study and applied to three geographically distinct cohorts. The Journal of Clinical Endocrinology & Metabolism 2011 96 8 2430 2439 2-s2.0-80051560339 10.1210/jc.2010-3012
8. Nieschlag E., Klinefelter syndrome: the commonest form of hypogonadism, but often overlooked or untreated. Deutsches Ärzteblatt International 2013 110 20 347 353 10.3238/arztebl.2013.0347
9. Jo D. G., Lee H. S., Joo Y. M., Seo J. T., Effect of testosterone replacement therapy on bone mineral density in patients with Klinefelter syndrome. Yonsei Medical Journal 2013 54 6 1331 1335 10.3349/ymj.2013.54.6.1331
10. Ferlin A., Schipilliti M., Vinanzi C., Garolla A., di Mambro A., Selice R., Lenzi A., Foresta C., Bone mass in subjects with Klinefelter syndrome: role of testosterone levels and androgen receptor gene CAG polymorphism. The Journal of Clinical Endocrinology & Metabolism 2011 96 4 E739 E745 2-s2.0-79953866977 10.1210/jc.2010-1878
11. Bojesen A., Birkebæk N., Kristensen K., Heickendorff L., Mosekilde L., Christiansen J. S., Gravholt C. H., Bone mineral density in Klinefelter syndrome is reduced and primarily determined by muscle strength and resorptive markers, but not directly by testosterone. Osteoporosis International 2011 22 5 1441 1450 2-s2.0-79955472500 10.1007/s00198-010-1354-7
12. Oostlander A. E., Bravenboer N., Sohl E., Holzmann P. J., van der Woude C. J., Dijkstra G., Stokkers P. C. F., Oldenburg B., Netelenbos J. C., Hommes D. W., van Bodegraven A. A., Lips P., Histomorphometric analysis reveals reduced bone mass and bone formation in patients with quiescent Crohn's disease. Gastroenterology 2011 140 1 116 123 2-s2.0-78650441283 10.1053/j.gastro.2010.09. 007
13. Oostlander A. E., Everts V., Schoenmaker T., Bravenboer N., Van Vliet S. J., van Bodegraven A. A., Lips P., de Vries T. J., T cell-mediated increased osteoclast formation from peripheral blood as a mechanism for Crohn's disease-associated bone loss. Journal of Cellular Biochemistry 2012 113 1 260 268 2-s2.0-84055218377 10.1002/jcb.23352
14. Oostlander A. E., Bravenboer N., van Essen H. W., Bone cells from patients with quiescent Crohn's disease show a reduced growth potential and an impeded maturation. Journal of Cellular Biochemistry 2012 113 7 2424 2431 10.1002/jcb.24119
15. Haider A., Kurtz W., Giltay E. J., Gooren L. J., Saad F., Administration of testosterone to elderly hypogonadal men with Crohn's disease improves their Crohn's disease activity index: a pilot study. Hormone Molecular Biology and Clinical Investigation 2010 2 3 287 292 10.1515/HMBCI.2010.033
16. Maurel D. B., Boisseau N., Benhamou C. L., Jaffre C., Alcohol and bone: review of dose effects and mechanisms. Osteoporosis International 2012 23 1 1 16 2-s2.0-84857371983 10.1007/s00198-011-1787-7
17. Kiserud C. E., Fosså A., Bjøro T., Holte H., Cvancarova M., Fosså S. D., Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. British Journal of Cancer 2009 100 3 455 463 2-s2.0-59649094063 10.1038/sj.bjc.6604892
18. Carrero J. J., Stenvinkel P., The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. Nephrology Dialysis Transplantation 2012 27 11 4030 4041 10.1093/ndt/gfs383
19. Martin Ritzén E., Bergh A., Bjerknes R., Christiansen P., Cortes D., Haugen S. E., Jörgensen N., Kollin C., Lindahl S., Läckgren G., Main K. M., Nordenskjöld A., Rajpert-De Meyts E., Söder O., Taskinen S., Thorsson A., Thorup J., Toppari J., Virtanen H., Nordic consensus on treatment of undescended testes. Acta Paediatrica 2007 96 5 638 643 2-s2.0-34247464721 10.1111/j.1651-2227.2006.00159.x (Pubitemid 46653166)
20. Heinemann L. A., Aging Males' Symptoms scale: a standardized instrument for the practice. Journal of Endocrinological Investigation 2005 28 11 34 38 2-s2.0-33746859070
21. Rosen R. C., Cappelleri J. C., Gendrano N. III, The International Index of Erectile Function (IIEF): a state-of-the-science review. International Journal of Impotence Research 2002 14 4 226 244 2-s2.0-0036668536 10.1038/sj.ijir.3900857 (Pubitemid 34947726)
22. Snyder P. J., Peachey H., Hannoush P., Berlin J. A., Loh L., Lenrow D. A., Holmes J. H., Dlewati A., Santanna J., Rosen C. J., Strom B. L., Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. The Journal of Clinical Endocrinology & Metabolism 1999 84 8 2647 2653 2-s2.0-0033307232 (Pubitemid 30641987)
23. Caminiti G., Volterrani M., Iellamo F., Marazzi G., Massaro R., Miceli M., Mammi C., Piepoli M., Fini M., Rosano G. M. C., Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. Journal of the American College of Cardiology 2009 54 10 919 927 2-s2.0-68949172537 10.1016/j.jacc.2009.04.078
24. Ferrando A. A., Sheffield-Moore M., Yeckel C. W., Gilkison C., Jiang J., Achacosa A., Lieberman S. A., Tipton K., Wolfe R. R., Urban R. J., Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. American Journal of Physiology 2002 282 3 E601 E607 2-s2.0-0036081614 10.1152/ajpendo.00362.2001 (Pubitemid 34654776)
25. Amory J. K., Watts N. B., Easley K. A., Sutton P. R., Anawalt B. D., Matsumoto A. M., Bremner W. J., Tenover J. L., Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. The Journal of Clinical Endocrinology & Metabolism 2004 89 2 503 510 2-s2.0-1442278883 10.1210/jc.2003-031110 (Pubitemid 38269849)
26. Wang C., Swerdloff R. S., Iranmanesh A., Dobs A., Snyder P. J., Cunningham G., Matsumoto A. M., Weber T., Berman N., Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clinical Endocrinology 2001 54 6 739 750 2-s2.0-0035725618 10.1046/j.1365-2265.2001.01271.x (Pubitemid 34208885)
27. Katznelson L., Finkelstein J. S., Schoenfeld D. A., Rosenthal D. I., Anderson E. J., Klibanski A., Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. The Journal of Clinical Endocrinology & Metabolism 1996 81 12 4358 4365 2-s2.0-0029838823 10.1210/jc.81.12.4358 (Pubitemid 26412044)
28. Behre H. M., Kliesch S., Leifke E., Link T. M., Nieschlag E., Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. The Journal of Clinical Endocrinology & Metabolism 1997 82 8 2386 2390 2-s2.0-0030852561 10.1210/jc.82.8.2386 (Pubitemid 27337844)
29. Snyder P. J., Peachey H., Hannoush P., Berlin J. A., Loh L., Holmes J. H., Dlewati A., Staley J., Santanna J., Kapoor S. C., Attie M. F., Haddad J. G. Jr., Strom B. L., Effect of testosterone treatment on bone mineral density in men over 65 years of age. The Journal of Clinical Endocrinology & Metabolism 1999 84 6 1966 1972 2-s2.0-0033304542 10.1210/jcem.84.6.5741 (Pubitemid 30647018)
30. Aversa A., Bruzziches R., Francomano D., Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. The Aging Male 2012 15 2 96 102 10.3109/13685538.2011.631230
31. Rodriguez-Tolra J., Torremade J., di Gregorio S., del Rio L., Franco E., Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome. Andrology 2013 1 4 570 575 10.1111/j.2047-2927.2013.00090.x
32. Aminorroaya A., Kelleher S., Conway A. J., Ly L. P., Handelsman D. J., Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. European Journal of Endocrinology 2005 152 6 881 886 2-s2.0-21344441718 10.1530/eje.1.01920 (Pubitemid 40903579)
33. Corona G., Vignozzi L., Sforza A., Maggi M., Risks and benefits of late onset hypogonadism treatment: an expert opinion. The World Journal of Men's Health 2013 31 2 103 125 10.5534/wjmh.2013.31.2.103
34. Corona G., Rastrelli G., Maggi M., Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Practice & Research Clinical Endocrinology & Metabolism 2013 27 4 557 579 10.1016/j.beem.2013.05.002
35. Kacker R., Conners W., Zade J., Morgentaler A., Bone mineral density and response to treatment in men less than fifty years with testosterone deficiency and sexual dysfunction or infertility. The Journal of Urology 2013 10.1016/j.juro.2013.10.070
36. Saad F., Gooren L. J., Haider A., Yassin A., A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. Journal of Andrology 2008 29 1 102 105 2-s2.0-38049169172 10.2164/jandrol.107.002774
37. Giltay E. J., Haider A., Saad F., Gooren L. J., C-reactive protein levels and ageing male symptoms in hypogonadal men treated with testosterone supplementation. Andrologia 2008 40 6 398 400 2-s2.0-57249092757 10.1111/j.1439-0272.2008.00873.x
38. Saad F., Haider A., Doros G., Traish A., Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity 2013 21 10 1975 1981 10.1002/oby.20407
39. Haider A., Gooren L. J. G., Padungtod P., Saad F., Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Experimental and Clinical Endocrinology & Diabetes 2010 118 3 167 171 2-s2.0-77949503625 10.1055/s-0029-1202774
40. Saad F., Gooren L., Haider A., Yassin A., An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Archives of Andrology 2007 53 6 353 357 2-s2.0-43749115158 10.1080/01485010701730880
41. Saad F., Gooren L., Haider A., Yassin A., Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome. Andrologia 2008 40 1 44 48 2-s2.0-38349016541 10.1111/j.1439-0272.2008.00807.x
42. Jacobsen S. J., Girman C. J., Guess H. A., Rhodes T., Oesterling J. E., Lieber M. M., Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. The Journal of Urology 1996 155 2 595 600 2-s2.0-0030064611 10.1016/S0022-5347(01)66461-9 (Pubitemid 26023551)
43. Anderson J. B., Roehrborn C. G., Schalken J. A., Emberton M., The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. European Urology 2001 39 4 390 399 2-s2.0-0035049190 10.1159/000052475 (Pubitemid 32304711)
44. Haider A., Gooren L. J., Padungtod P., Saad F., Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia 2009 41 1 7 13 2-s2.0-58449124744 10.1111/j.1439-0272.2008.00880.x
45. Haider A., Gooren L. J. G., Padungtod P., Saad F., A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months. Andrologia 2010 42 6 349 355 2-s2.0-78649582389 10.1111/j.1439-0272.2009.01016.x
46. Morgentaler A., Testosterone and prostate cancer: what are the risks for middle-aged men? Urologic Clinics of North America 2011 38 2 119 124 2-s2.0-79957514411 10.1016/j.ucl.2011.02.002